Take a trial of UK to unlock this pageFind out more


GSK 1457p 3.0  0.2%
26/05/16 1.50k

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed 3 / 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2010 2011 2012 2013 2014 2015 TTM 2016E 2017E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Last ex-div: 12th May, paid: 14th Jul more... Dividends
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p -9.3%

FINANCIAL BRIEF: For the three months ended 31 March 2016, GlaxoSmithKline plc revenues increased 11% to L6.23B. Net income decreased 97% to L282M. Revenues reflect Consumer Healthcare segment increase of 27% to L1.76B, Vaccines segment increase of 26% to L882M, Pharmaceuticals segment increase of 2% to L3.59B, USA segment increase of 16% to L2.07B, Europe segment increase of 17% to L1.82B, Emerging Markets segment increase of 3% to L2.34B. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 31st Mar '16) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2016
31st Dec 2017

Price Target: 15.2
(+4.61% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: +6.7% (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
29 brokers Broker Consensus Trend
Broker Recommendations for GlaxoSmithKline
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 2 18 6 3

Named Brokers and Analysts
Jefferies Jeffrey Holford , Credit Suisse Rebekah Harper , Leerink Partners LLC Seamus Fernandez , BERNSTEIN Tim Anderson , Panmure Gordon , Natixis Philippe Lanone , Mirabaud Securities Nicholas Turner , Societe Generale Florent Cespedes , Berenberg Alistair Campbell , Oddo Securities Sebastien Malafosse , Helvea SA Odile Rundquist , Hamburger Sparkasse (HASPA) Marco Gunther , Cenkos Securities Navid Malik , Shore Capital Stockbrokers Tara Raveendran , Bryan Garnier Eric Le Berrigaud , Morningstar, Inc. Damien Conover , Day by Day Valérie GASTALDY , Landesbank Baden-Wuerttemberg Timo Kuerschner , Liberum Naresh Chouhan , Cantor Fitzgerald Europe Brian White , Baader Helvea Equity Research Odile Rundquist ,

Profile Summary

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases.

Directors: Andrew Witty (CEO) 50, Simon Dingemans (CFO) 51, Moncef Slaoui (CEX) 55, Roger Connor (CEX) , Abbas Hussain (CEX) , Shah Abbas Hussain (CEX) 49, Patrick Vallance (CEX) , Emma Walmsley (CEX) , Daniel Troy (SVP) , Claire Thomas (SVP) , Philip Hampton (NEC) 61, Jesse Goodman (NED) , Roy Anderson (NID) 68, Manvinder Banga (NID) 61, Stacey Cartwright (NID) 51,

No. of Employees: 101,192 No. of Shareholders: 135,166

Last Annual December 31st, 2015
Last Interim March 31st, 2016
Incorporated December 6, 1999
Public Since May 22, 1972
Shares in Issue 4,871,492,413
Free Float 4.83bn (99.2%)

Address 980 Great West Road, BRENTFORD, TW8 9GS, United Kingdom
Web http://www.gsk.com
Phone +44 20 80475000
Contact ()
Auditors PricewaterhouseCoopers LLP

GSK Share Price Performance GSKQuote
3.0  0.2%
Traded 4:37pm · Minimum 15 min delayed · NMS: 1.50k

Latest GSK News Announcements (delayed)

Upcoming GSK Events
Wednesday 8th June, 2016
GlaxoSmithKline PLC at Goldman Sachs Global Healthcare Conference
Wednesday 27th July, 2016
Q2 2016 GlaxoSmithKline PLC Earnings Release
Wednesday 26th October, 2016
Q3 2016 GlaxoSmithKline PLC Earnings Release

Recent ↓
Thursday 12th May, 2016
Dividend For GSK.L
Wednesday 11th May, 2016
Dividend For GSK
Wednesday 11th May, 2016
Dividend For GSK.BA
Thursday 5th May, 2016
GlaxoSmithKline PLC Annual Shareholders Meeting
Wednesday 27th April, 2016
Q1 2016 GlaxoSmithKline PLC Earnings Call
Wednesday 27th April, 2016
Q1 2016 GlaxoSmithKline PLC Earnings Release
Tuesday 1st March, 2016
GlaxoSmithKline PLC at Credit Suisse One-on-One Healthcare Conference
Thursday 18th February, 2016
Dividend For GSK.L
Thursday 18th February, 2016
Dividend For GSK.L
Wednesday 17th February, 2016
Dividend For GSK
Wednesday 17th February, 2016
Dividend For GSK
Wednesday 17th February, 2016
Dividend For GSK.BA
Wednesday 17th February, 2016
Dividend For GSK.BA
Wednesday 10th February, 2016
GlaxoSmithKline PLC at Leerink Partners Global Healthcare Conference
Wednesday 3rd February, 2016
Q4 2015 GlaxoSmithKline PLC Earnings Call
Wednesday 3rd February, 2016
Q4 2015 GlaxoSmithKline PLC Earnings Release
Tuesday 2nd February, 2016
Adaptimmune Therapeutics PLC to Discuss Expansion of Strategic Collaboration Agreement with GlaxoSmithKline (GSK) Call
Tuesday 12th January, 2016
GlaxoSmithKline PLC at JPMorgan Healthcare Conference
Friday 18th December, 2015
GlaxoSmithKline PLC Buys Bristol-Myers Squibb's HIV Assets - Conference Call
Thursday 12th November, 2015
Dividend For GSK.L

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2016.

Should you buy GSK

Access GSK Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis